ERS Genomics grants Transomic access to CRISPR/Cas9 portfolio
In a non-exclusive licensing agreement, ERS Genomics has granted Transomic Technologies access to the foundational ERS CRISPR/Cas9 patent portfolio.
If you are not happy with the results below please do another search
In a non-exclusive licensing agreement, ERS Genomics has granted Transomic Technologies access to the foundational ERS CRISPR/Cas9 patent portfolio.
TransCure bioServices, a humanized mouse model CRO, has partnered with Preclina, a South Korean preclinical CRO specializing in autoimmune and inflammatory diseases. The partnership significantly expands TransCure’s reach into the APAC region, while also bolstering its service offerings to further enhance the quality of its research results.
Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of bio-pharmaceutical drugs, will collaborate with RheaVita in an effort to pave the way for drug development of biologics using RheaVita’s novel single vial unit (SVU) technology for continuous and controlled freeze-drying technology, particularly to stabilize novel […]
• Novel non-viral gene delivery platform to help advance tissue repair following orthopaedic surgery • Funding from Innovate UK’s Transforming Medicines Manufacturing programme supporting innovative technologies for intracellular drug delivery
AntlerA Norrin/Wnt-agonist antibody, through a strategic partnership with EyeBio, has entered clinical trials for treatment of retinopathies.
Genomic Vision, a Euronext-listed biotechnology company that develops products and services for the characterization of DNA sequences, has secured an exclusive European distribution agreement with CliniSciences.
GBA Group, a leading European life science service provider, has entered the U.S. market with a site in Westborough, Massachusetts to support clinical trials. Located in the greater Boston area, a pharmaceutical and biotech hub, the laboratory and logistics site will be fully operational in October this year and will offer a broad range of […]
Appointment part of company’s ambitious global growth strategy
Avacta Group has acquired Coris Bioconcept for £7.4 million and an extra £3 million payout based on future business performance.
Scientists have taken an important step forward in predicting who will develop Type 1 diabetes months before symptoms appear.